United Kingdom

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

23 May 2018
Change (% chg)

$-0.35 (-1.77%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Stemline Therapeutics reports Q3 loss per share $0.68
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Stemline Therapeutics Inc :Stemline Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.68.Q3 earnings per share view $-0.59 -- Thomson Reuters I/B/E/S.Stemline Therapeutics-‍stemline ended Q3 of 2017 with $79.9 million in cash, cash equivalents and investments, as compared to $93.2 million as of June 30, 2017​.  Full Article

Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 has met its primary endpoint​
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Stemline Therapeutics Inc :Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm has met its primary endpoint​.Stemline Therapeutics Inc - ‍based on feedback from U.S. FDA, co remains on track to begin submission of BLA in 4Q17-1Q18 timeframe for SL-401​.  Full Article

Stemline Therapeutics Q4 loss per share $0.56
Thursday, 16 Mar 2017 

Stemline Therapeutics Inc : Stemline therapeutics reports fourth quarter 2016 financial results . Q4 loss per share $0.56 . Q4 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S .Qtrly grant revenue $299,401 versus $205,651.  Full Article

Stemline Therapeutics Q2 loss per share $0.52
Thursday, 4 Aug 2016 

Stemline Therapeutics Inc : Q2 loss per share $0.52 . Stemline Therapeutics reports second quarter 2016 financial results and highlights recent clinical progress .Q2 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.  Full Article